Biogen (BIIB) Plans to Spinoff Hemophilia Business into Independent, Publicly-Traded Company

May 3, 2016 7:31 AM EDT Send to a Friend
Biogen Inc. (NASDAQ: BIIB) announced that it intends to spin off its hemophilia business as an independent, publicly traded company ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to Premium below (Free Trial) LEARN MORE

Member Login